Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > 75 to 100 patients
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(606)
•••
Comment by O12009on Aug 12, 2024 9:44pm
180 Views
Post# 36175710

RE:RE:RE:RE:75 to 100 patients

RE:RE:RE:RE:75 to 100 patients

Please click the Press Release link to view our latest news release, which includes our second quarter financials and our much-anticipated update on our late-stage clinical trial.

Key highlights from the Press Release:

  • 72 Patients treated
  • 63% Complete Response
  • 48% Duration of Complete Response at 1 year
  • 44% Duration of Complete Response at 15 months
  • 90% of patients who achieve Complete Response at 450 days continue this response beyond 450 days

We are very encouraged by these best-in-class duration results demonstrating a duration or reponse of over 3 years for many patients. 

Additionally for more information, view this interview with Roger, where he discusses our latest clinical study achievements.

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities